3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Myelodysplastic Syndromes
27
Leukemia, Myeloid, Acute
27
Leukemia, Myelomonocytic, Chronic
10
Myeloproliferative Disorders
8
Primary Myelofibrosis
4
Myelodysplastic-Myeloproliferative Diseases
4
Thrombocythemia, Essential
3
Polycythemia Vera
3
Leukemia, Biphenotypic, Acute
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Mastocytosis
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Interventions
masitinib
4
Imatinib Mesylate
3
midostaurin
1
fludarabine phosphate
1
fludarabine
1
avapritinib
1
Whole-Body Irradiation
1
Watchful Waiting
1
Transplantation
1
Tacrolimus
1
Stem Cell Transplantation
1
Sodium Chloride
1
Single-Cell Gene Expression Analysis
1
Radiotherapy
1
Phlebotomy
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Mass Screening
1
Injections
1
Hydroxychloroquine
1
Dasatinib
1
Cyclophosphamide
1
Cromolyn Sodium
1
Cladribine
1
Busulfan
1
BNT162 Vaccine
1
AK002
1
2019-nCoV Vaccine mRNA-1273
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mastocytosis
×
Injections
×
Myeloid
×
Clear all
NCT01333293
2016-01-18
XOLMA
University of Zurich
Phase 2/3
Completed
17 enrolled